Total medical devices industry venture financing deals worth $1.4bn were announced in the US in April 2021, led by $150m venture financing of Inscripta, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 15.5% over the previous month of $1.23bn and a rise of 59.5% when compared with the last 12-month average of $890.41m.
The US held a 65.44% share of the global medical devices industry venture financing deal value that totalled $2.17bn in April 2021.
In terms of venture financing deal activity, the US recorded 56 deals during April 2021, marking a decrease of 13.85% over the previous month and a drop of 1.75% over the 12-month average.
US medical devices industry venture financing deals in April 2021: Top deals
The top five medical devices industry venture financing deals accounted for 44.7% of the overall value during April 2021.
The combined value of the top five medical devices venture financing deals stood at $633m, against the overall value of $1.4bn recorded for the month.
The top five medical devices industry venture financing deals of April 2021 tracked by GlobalData were:
1) Counterpoint Global,D1 Capital Partners,Durable Capital Partners,Fidelity Management & Research,Foresite Capital Management,JS Capital and T Rowe Price Associates $150m venture financing deal with Inscripta
2) The $150m venture financing of EDDA Technology by 3W Partners,Orbimed Advisors and SoftBank Vision Fund II
3) Tiger Global Management $133m venture financing deal with Virta Health
4) The $100m venture financing of Caresyntax by Arno Capital,Intel Capital,IPF Management,Lauxera Capital Partners,Optum Ventures,PFM Health Sciences,Relyens,Rezayat Investments,Surgical.ai and Vesalius Biocapital III Partners
5) aMoon Partners,Anthem,Blue Ox Healthcare Partners SP,Parian Global Management and Vivo Capital $100m venture financing deal with Sera Prognostics
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.